MedPharm and Mosanna collaboration to develop novel Metabolic Obstructive Sleep Apnea treatment
A collaboration between development and manufacturing services company MedPharm and biotech company Mosanna aims to develop and deliver a nasal spray treatment for a form of sleep apnea.
Contract topical and transdermal formulation development and manufacturing services company MedPharm (Guildford, UK) have announced their collaboration with Swiss biotech company Mosanna Therapeutics for the development of a nasal spray treatment for Metabolic Obstructive Sleep Apnea (MOSA).
MOSA occurs from the collapsing of the airway during sleep, affecting up to 1 billion individuals worldwide. Adverse metabolic and cardiovascular events are associated with both repeated partial and/or complete obstruction of the upper airway during sleep. This can often lead to a severe impact on the quality of life of those who suffer from the disease. Currently, continuous positive airway pressure (CPAP) is the most common method of treating MOSA. With up to 30% of patients not tolerating this form of treatment, these individuals have few pharmaceutical options available.
The development of the MOS-118 nasal spray by Mosanna functions by preventing airway collapse during sleep. The collaboration of Mosanna with MedPharm aims at precisely engineering a product that can deliver MOS-118 in a nasal spray form, acting locally in the upper airway overnight. Proprietary nasal testing models from MEdPharm will optimize the formulation and delivery of the product into the nasal cavitiy.
MedPharm President and CEO, Eugene Ciolgi, commented on the collaboration: “MedPharm’s primary mission is to support the development of life-changing therapeutics, and Mosanna’s nasal spray is a promising opportunity to do just that. We are excited to work with their team of experienced industry leaders to realise MOS-118's potential with the end goal of imrpoving the quality of life for those living with Metabolit Obstructive Sleep Apnea.”
Jonathan Talbot, CEO of Mosanna, added: “MedPharm is world-renowned for its dermal and transdermal capabilities including intranasal delivery routes, so [it] was a clear first choice for this project. I am also excited by the potential this partnership creates for additional projects on the horizon for Mosanna.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance